Reply to: Appearances are often deceptive

• References

• 1 Boy C, Poeppel T, Kotzerke J. et al. Somatostatin receptor PET/CT (SSTR-PET/CT). Nuklearmedizin 2018; 57: 4-17.
• 2 Hicks RJ, Kwekkeboom DJ, Krenning E. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017; 105: 295-309.
• 3 Hope TA, Bergsland EK, Bozkurt MF. et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018; 59: 66-74.
• 4 Poeppel TD, Boy C, Bockisch A. et al. Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1). Nuklearmedizin 2015; 54: 1-11.
• 5 Rinke A, Wiedenmann B, Auernhammer C. et al. Practice guideline neuroendocrine tumors – AWMF-Reg. 021–27. Z Gastroenterol 2018; 56: 583-681.
• 6 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 12 (376) 125-135.
• 7 Sundin A, Arnold R, Baudin E. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology 2017; 105: 212-244.